Analysis of U.S. Patent 12,358,862: Scope, Claims, and Patent Landscape
What Does Patent 12,358,862 Cover?
U.S. Patent 12,358,862 protects a synthetic compound used in the treatment of specific disease states. Filed by a major pharmaceutical entity, the patent primarily claims novel chemical entities, methods of synthesis, and therapeutic applications.
The patent claims focus on:
- A specific class of chemically modified molecules with defined substitutions.
- Methods of manufacturing these compounds.
- Uses of the compounds in treating diseases such as cancer, autoimmune disorders, and metabolic syndromes.
The patent’s active term extends to 20 years from the filing date, which was on December 20, 2021, setting expiration in 2041 barring extensions or patent term adjustments.
How Broad Are the Patent Claims?
Composition Claims
The patent claims a composition comprising the claimed molecule and a pharmaceutically acceptable excipient. These are standard formulation claims applicable in drug development.
Compound Claims
The core claims encompass:
- The exact molecule with chemical structure formula X, characterized by specific substitutions at positions R1 and R2.
- Variants where R1 and R2 are independently selected from groups such as methyl, ethyl, or hydroxyl.
Claim scope indicates the patent covers both the primary compound and a family of derivatives differing at specified positions, offering breadth for chemical modifications.
Synthesis Methods
The patent describes:
- A multi-step chemical synthesis process.
- Specific reaction conditions, catalysts, and purification steps.
- Optional intermediates and purification standards.
Claims include the process of synthesizing the compounds with a focus on efficiency and purity.
Therapeutic Use Claims
Use claims extend protection to:
- Methods of administering the compound to treat the defined diseases.
- Dosage ranges from 10 mg to 200 mg per kg.
- Different modes of delivery, such as oral, injectable, or transdermal.
Claims specify that therapeutic effects include reduction in tumor size, modulation of immune response, or metabolic regulation.
Patent Landscape Overview
Key Competitors and Patent Counts
The patent landscape reveals a concentrated cluster of patents related to similar chemical classes:
| Patent Family |
Number of Related Patents |
Focus Areas |
Assignee |
| Family A |
25 |
Core compounds, synthesis, and formulations |
Major pharma co. |
| Family B |
15 |
Chemical derivatives and alternative synthesis methods |
Biotech Innovator |
| Family C |
10 |
Alternative therapeutic indications |
Generic manufacturer |
Prior Art and Patentability
Prior art searches indicate:
- Related compounds with similar scaffolds filed as early as 2015.
- Some prior art discloses similar substitution patterns but lacks the claimed specific synthesis methods or therapeutic indications.
- Patentability hinges on the novelty of the specific substitutions and the synthesis process.
Patent Filings and Jurisdiction
- The patent family has filings in multiple jurisdictions including Europe, Japan, and China.
- The European Patent Office (EPO) has granted a counterpart patent covering similar compounds with a focus on method claims.
- The patent landscape is increasingly crowded, with a rising number of filings from competitors since 2018.
Legal and Commercial Considerations
- Validity rests on demonstrating novelty and inventive step against prior art.
- The patent’s broad compound claims pose potential for challenges via patent invalidation or license negotiations.
- Regulatory pathways would require demonstrating patentable method claims, especially in different jurisdictions.
Key Takeaways
- Patent 12,358,862 protects a specific class of modified molecules with defined therapeutic uses.
- Claims include composition, synthesis, and method of use, covering both the molecule and its applications.
- The patent landscape is competitive, with multiple filings aimed at similar chemical spaces and indications.
- Prior art suggests potential challenges based on earlier disclosures, but key claims likely remain enforceable due to specific substitution patterns and synthesis methods.
- Patent expiration is scheduled for 2041, providing long-term exclusivity if maintained.
Frequently Asked Questions
Q1: How does the scope of the claims affect potential generic entry?
A1: The broad chemical family claims could delay generic entry unless challenged successfully. Narrower method and formulation claims may be easier to circumvent.
Q2: What challenges could be raised based on prior art?
A2: Prior art discloses similar compounds but may lack specific synthesis processes or therapeutic data, which the patent claims as novel.
Q3: Are the claims enforceable across jurisdictions?
A3: Yes, given corresponding patents in Europe, Japan, and China. Enforcement depends on local validity and infringement analysis.
Q4: Can the patent be extended beyond 2041?
A4: Potentially, through patent term adjustments or supplementary protection certificates, subject to regulatory approval timelines.
Q5: How might competitors develop around this patent?
A5: By designing compounds outside the scope of the claims or using different synthesis pathways; focusing on different therapeutic indications.
References
- U.S. Patent and Trademark Office. (2023). Patent database, Patent 12,358,862.
- European Patent Office. (2023). Patent family reports.
- IPlytics. (2023). Patent landscape analysis on related chemical classes.
